产品
编 号：F748099
产品类型
规格
价格
是否有货
结构图
CAS No: 1957239-90-5
产品详情
生物活性：
Bifikafusp alfa (L19-IL2) is an immunoresearch fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity.
体内研究：
Bifikafusp alfa (1.43 and 4.29 MIU/kg; i.p.; daily; for 10 days; 雌性 NMRI 裸鼠 MiaPaca-A2 异种移植) 对已建立的胰腺癌具有抗肿瘤活性。Animal Model:Female NMRI nude mice with MiaPaca-A2 xenografts
Dosage:1.43 and 4.29 MIU/kg
Administration:Intraperitoneal injection; daily; for 10 days
Result:Reduced tumor volume to 21.4% (1.43 MIU/kg) and 2.7% (4.29 MIU/kg) compared with control mice.
Bifikafusp alfa (L19-IL2) is an immunoresearch fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity.
体内研究：
Bifikafusp alfa (1.43 and 4.29 MIU/kg; i.p.; daily; for 10 days; 雌性 NMRI 裸鼠 MiaPaca-A2 异种移植) 对已建立的胰腺癌具有抗肿瘤活性。Animal Model:Female NMRI nude mice with MiaPaca-A2 xenografts
Dosage:1.43 and 4.29 MIU/kg
Administration:Intraperitoneal injection; daily; for 10 days
Result:Reduced tumor volume to 21.4% (1.43 MIU/kg) and 2.7% (4.29 MIU/kg) compared with control mice.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备